Updated results of a phase II study of RC48 in combination with tislelizumab as pre-transurethral resection neoadjuvant therapy for extensive high-risk non–muscle-invasive bladder cancer with HER2 overexpression.

Authors: Yunkai Qie, Kaipeng Jia, Hailong Hu, Chong Shen, Zhouliang Wu, Shiwang Huang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16596

Source: Full article

e16596